Skip to main content

Table 1 Clinical characteristics of patients

From: Increased platelet expression of FcGammaRIIa and its potential impact on platelet reactivity in patients with end stage renal disease

Characteristic

Low FcγRIIa

High FcγRIIa

 
 

n (%)

n (%)

p value

Age (mean ± SD)

67 ± 15

67 ± 12

1

male

8 (50%)

10 (63%)

0.87

CAD

11 (71%)

10 (63%)

0.82

CVA/TIA

2 (12%)

7 (44%)

0.15

Hypertension

13 (76%)

16 (100%)

0.55

Diabetes

10 (61%)

10 (63%)

0.89

Hyperlipidemia

11 (65%)

9 (56%)

0.57

Treatment with

   

aspirin

9 (53%)

11(69%)

0.89

warfarin

3 (18%)

3 (19%)

0.71

thienopyridine

3 (18%)

5 (31%)

0.64

β blocker

8 (47%)

11 (69%)

0.36

Calcium blocker

7 (41%)

5 (31%)

0.81

ACEI/ARB

7 (41%)

4 (25%)

0.55

insulin

5 (29%)

7 (44%)

0.59

oral hypoglycemic

3 (18%)

3 (19%)

0.71

Duration of HD (mo – mean ± SD)

31 ± 25

32 ± 23

0.91

  1. CAD = coronary arterial disease, CVA = cerebrovascular accident, TIA = transient ischemic attack, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, HD = hemodialysis, mo = month
Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us